Gossamer Bio Stock Surges on FDA Progress and Worldwide Rights Win for Seralutinib
A productive FDA Pre-NDA meeting paves the way for a September 2026 NDA filing for seralutinib in PAH and the return of full rights.
/ 2 items
A productive FDA Pre-NDA meeting paves the way for a September 2026 NDA filing for seralutinib in PAH and the return of full rights.
Gossamer Bio’s seralutinib narrowly missed its Phase 3 target for pulmonary arterial hypertension, yet delivered strong benefits in higher-risk patients. Company still plans FDA talks.